NEW YORK (GenomeWeb News) – Asterand said today that it will validate and characterize antibodies and immunohistochemistry applications for antibody marketer Abcam.

Under the collaborative agreement, Asterand will use its PhaseZero Human Tissue Services platform and its Target Evaluator gene expression database to select antibodies and to identify expression patterns for their use with human tissue.

The resulting data will be incorporated into Abcam’s literature and technical support documentation for each antibody tested and will be sold through its online catalogue.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.